Influenza B Infections - Pipeline Review, H2 2016 - Global Markets Direct - Market Research

Influenza B Infections - Pipeline Review, H2 2016

Influenza B Infections - Pipeline Review, H2 2016 - Global Markets Direct - Market Research
Influenza B Infections - Pipeline Review, H2 2016
Published Jul 30, 2016
71 pages — Published Jul 30, 2016
Price US$ 2,000.00  |  Buy this Report Now

About This Report

  
Abstract:

Summary

Global Markets Directs, Influenza B Infections - Pipeline Review, H2 2016, provides an overview of the Influenza B Infections pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Influenza B Infections, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Influenza B Infections and features dormant and discontinued projects.

Global Markets Directs report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Directs proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape of Influenza B Infections
- The report reviews pipeline therapeutics for Influenza B Infections by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved Influenza B Infections therapeutics and enlists all their major and minor projects
- The report assesses Influenza B Infections therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news related to pipeline therapeutics for Influenza B Infections

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of therapeutics under development for Influenza B Infections
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and its most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Influenza

  
Source:
Document ID
GMDHC8313IDB
Industry
Format:
PDF Adobe Acrobat
Buy Now

Sections

TitleStarting PageNumber of Pages
Table of Contents25
  List of Tables51
  List of Figures61
Introduction71
  Global Markets Direct Report Coverage71
Influenza B Infections Overview81
Therapeutics Development92
  Pipeline Products for Influenza B Infections Overview91
  Pipeline Products for Influenza B Infections Comparative Analysis101
Influenza B Infections Therapeutics under Development by Companies111
Influenza B Infections Therapeutics under Investigation by Universities/Institutes121
Influenza B Infections Pipeline Products Glance133
  Late Stage Products131
  Clinical Stage Products141
  Early Stage Products151
Influenza B Infections Products under Development by Companies161
Influenza B Infections Products under Investigation by Universities/Institutes171
Influenza B Infections Companies Involved in Therapeutics Development1813
  AbbVie Inc.181
  Altravax, Inc.191
  Aphios Corporation201
  BioClonetics Immunotherapeutics, Inc.211
  ContraFect Corporation221
  Humabs BioMed SA231
  Johnson &Johnson241
  Medicago Inc.251
  MedImmune, LLC261
  Mucosis B.V.271
  Sanofi Pasteur SA281
  Vaxart, Inc.291
  Zydus Cadila Healthcare Limited301
Influenza B Infections Therapeutics Assessment319
  Assessment by Monotherapy Products311
  Assessment by Combination Products321
  Assessment by Target332
  Assessment by Mechanism of Action351
  Assessment by Route of Administration362
  Assessment by Molecule Type382
Drug Profiles4026
  AL-18 Drug Profile401
  APP-0205 Drug Profile411
  APP-309 Drug Profile421
  CF-403 Drug Profile431
  CR-8033 Drug Profile441
  CR-8071 Drug Profile451
  CR-9114 Drug Profile461
  Fluad (quadrivalent) Drug Profile471
  FluGEM Drug Profile481
  influenza [serotype B] vaccine Drug Profile491
  influenza [serotypes A, B] (split virion, tetravalent) vaccine Drug Profile501
  influenza [serotypes A, B] (virus like particle) vaccine Drug Profile511
  influenza [strains A/H1N1 + A/H3N2 + B/Victoria + B/Yamagata] (quadrivalent) vaccine Drug Profile521
  influenza [strains A/H1N1 + A/H3N2 + B/Victoria + B/Yamagata] (tetravalent, split virion) vaccine Drug Profile531
  influenza [strains A/H1N1 + A/H3N2 + B/Yamagata + B/Victoria] (quadrivalent) vaccine Drug Profile541
  influenza [strains A/H1N1 + A/H3N2 + B/Yamagata + B/Victoria] (quadrivalent, virus like particle) vaccine Drug Profile553
  influenza [strains A/H1N1 + A/H3N2 + B/Yamagata] (trivalent, split virion) vaccine Drug Profile581
  influenza [strains A/H1N1 + A/H3N2 + B/Yamagata] (trivalent, virus like particle) vaccine Drug Profile591
  influenza [strains A/H1N1 + A/H3N2 + B] (quadrivalent) vaccine Drug Profile601
  influenza [strains A/H1N1 + A/H3N2 + B] (trivalent, split virion) vaccine Drug Profile611
  influenza [strains A/H1N1 + A/H3N2 + B] (trivalent, split virion) vaccine Drug Profile621
  Monoclonal Antibody for Influenza B Drug Profile631
  Monoclonal Antibody for Influenza B Infections Drug Profile641
  VXABYW-10 Drug Profile651
Influenza B Infections Dormant Projects661
Influenza B Infections Discontinued Products671
Influenza B Infections Product Development Milestones682
  Featured News &Press Releases681
    Dec 17, 2015: Vaxart Announces Enrollment of First Patient in Influenza B Phase 1 Trial681
    Mar 11, 2011: Sanofi Pasteur And Daiichi Sankyo Announce Voluntary Recall Of Hemophilus Influenza Type B Conjugate Vaccine691
    Apr 23, 1993: FDA Approval of Use of a New Haemophilus b Conjugate Vaccine and a Combined Diphtheria-Tetanus-Pertussis and Haemophilus b Conjugate Vaccine for Infants and Children691
Appendix702
  Methodology701
  Coverage701
  Secondary Research701
  Primary Research701
  Expert Panel Validation701
  Contact Us701
  Disclaimer711

Table Of Contents

Global Markets Direct - Market Research—Global Markets Direct is a leading provider of global business intelligence and market analysis. It publishes a range of high quality market reports created by its large research and analysis capability and drawing from its extensive unique databases of industry-specific information.

About the Author


Cite this Report

  
MLA:
Global Markets Direct - Market Research. "Influenza B Infections - Pipeline Review, H2 2016" Jul 30, 2016. Alacra Store. Nov 16, 2026. <http://www.alacrastore.com/storecontent/Global-Markets-Direct-Market-Research/Influenza-B-Infections-Pipeline-Review-H2-2016-2088-16303>
  
APA:
Global Markets Direct - Market Research. (2016). Influenza B Infections - Pipeline Review, H2 2016 Jul 30, 2016. New York, NY: Alacra Store. Retrieved Nov 16, 2026 from <http://www.alacrastore.com/storecontent/Global-Markets-Direct-Market-Research/Influenza-B-Infections-Pipeline-Review-H2-2016-2088-16303>
  
US$ 2,000.00
$  £  €
Have a Question?

Any questions about the report you're considering? Our Customer Service Team can help! Or visit our FAQs.

More Research

Search all our Market Research from one place.